Open Access

Lipid profile abnormalities seen in T2DM patients in primary healthcare in Turkey: a cross-sectional study

Lipids in Health and Disease201413:183

https://doi.org/10.1186/1476-511X-13-183

Received: 28 August 2014

Accepted: 29 November 2014

Published: 6 December 2014

Abstract

Background

Diabetes is characterized by chronic hyperglycemia and disturbances of carbohydrate, lipid and protein metabolism. We aimed to research association between serum lipid profile and blood glucose, hypothesizing that early detection and treatment of lipid abnormalities can minimize the risk for atherogenic cardiovascular disorder and cerebrovascular accident in patients with type 2 diabetes mellitus.

Methods

Fasting blood glucose (FBG), total cholesterol (TC), high density lipoprotein (HDL), low density lipoprotein (LDL), triglyceride (TG) and glycated haemoglobin (HbA1c) levels were evaluated. A hepatic ultrasound was performed for every diabetic to evaluate hepatosteatosis. The study was done from January 2014 to June 2014 among 132 patients with T2DM who were admitted to outpatient clinic of Family Medicine department in a university hospital. The patients whose taking multi-vitamin supplementation or having hepatic, renal or metabolic bone disorders (including parathyroid related problems) were excluded from the study for the reason that those conditions might affect the carbohydrate and lipid metabolism in diabetes. Test of significance was calculated by unpaired student’s t test between cases and controls. Correlation studies (Pearson’s correlation) were performed between the variables of blood glucose and serum lipid profile. Significance was set at p<0.05.

Results

Results of serum lipid profile showed that the mean values for TC, TG, HDL and LDL in female patients were 227.6 ± 57.7 mg/dl, 221.6 ± 101.1 mg/dl, 31.5 ± 6.7 mg/dl and 136.5 ± 43.7 mg/dl, respectively. The mean values for TC, TG, HDL and LDL in male patients were 219.1 ± 34.7 mg/dl, 250.0 ± 100.7 mg/dl, 30.2 ± 7.4 mg/dl and 125.7 ± 21.4 mg/dl, respectively. Significantly higher mean serum levels of TC, TG and LDL and significantly lower mean serum levels of HDL were noted in patients with diabetes (p<0.001). FBG showed significant positive correlation with TC (p<0.05) and TG (p<0.05). Significant correlations were observed between serum levels of TC, TG, LDL and hepatosteatosis and HbA1c (p<0.05).

Conclusions

The study showed widespread lipid abnormalities in the course of diabetes triggered dyslipidemia as hypercholesterolemia, hypertriglyceridemia, elevated LDL and decreased HDL. This study proposes the predominance of hyperlipidemia over increased prevalence of diabetic dyslipidemia.

Keywords

Dyslipidemia Glucose intolerance Insulin resistance Type 2 diabetes Lifestyle modification

Background

Diabetes mellitus is a common metabolic disorder characterized by absolute or relative deficiencies in insulin secretion and/or insulin action associated with chronic hyperglycemia and disturbances of carbohydrate, lipid and protein metabolism [1]. Several previous studies have attempted to correlate blood glucose levels with serum lipid profile parameters [2, 3]. Research findings show that mainly body fat is responsible for increase in prevalence of this disease among the body composition components [1, 4, 5]. As early as 1988, it was described a multifactorial metabolic abnormality consisting of insulin resistance with compensatory hyperinsulinaemia, type 2 diabetes mellitus (T2DM), essential hypertension and hypercholesterolaemia [6, 7]. Today, however, the World Health Organization (WHO) and International Diabetes Federation (IDF) use the term “Metabolic Syndrome” to describe this clustering of conditions [8]. The term diabetic dyslipidemia comprises a triad of raised triglycerides, reduced high density lipoprotein (HDL) and excess of small, dense low density lipoprotein (LDL) particles. The lipid abnormalities are prevalent in diabetes mellitus because insulin resistance or deficiency affects key enzymes and pathways in lipid metabolism [9]. Micro-vascular and macro-vascular complications, including cardiovascular disease (CVD), retinopathy, nephropathy, and neuropathy, occur due to chronic uncontrolled hyperglycemia in diabetics [10, 11]. It has been proposed that the composition of lipid particles in diabetic dyslipidemia is more atherogenic than other types of dyslipidemia [12]. The causal association between atherosclerosis and dyslipidemia is well established. In diabetes the associated hyperglycemia, obesity and insulin changes highly accelerate the progression to atherosclerosis [13, 14]. In a recent study, it was observed significant trends for rising risk of coronary heart disease, stroke and all-cause mortality in relation to higher levels of baseline HbA1c in more than 11,000 participants in the Atherosclerosis Risk in Communities Study. For HbA1c categories of <6.5% and ≥ 6.5%, there was a significant association between fasting blood glucose levels and coronary heart disease, stroke or death from any cause [15]. It was attempted to correlate blood glucose levels with serum lipid profile parameters in previous studies [2] and it is clear that HbA1c values are lower in individuals with a decreased risk of micro-vascular complications [15].

In the present study, we aimed to research association between serum lipid profile and blood glucose, hypothesizing that early detection and treatment of lipid abnormalities can minimize the risk for atherogenic cardiovascular disorder and cerebrovascular accident in patients with type 2 diabetes mellitus.

Results

We evaluated clinical and laboratory findings in 132 patients with T2DM. Of the total number of subjects, 61.4% (81) were females, and 38.6% (51) of the subjects were males (Table 1). The age range and mean age of female subjects was 37–75 years and 55.5 ± 9.2 while the age range and mean age for male subjects was 39–84 years and 54.8 ± 12.6 years, respectively. The mean BMI of the participants was 28.59 ± 3.25 kg/m2 (range: 26.10-44.98). Eleven out of 132 patients were obese in this study with BMI ranging from 31.02 to 44.98.
Table 1

Gender distribution and age of patients with type 2 diabetes

Gender

No. of patients

Age1

Female

81

55.5 ± 9.2

Male

51

54.8 ± 12.6

Total

132

55.3 ± 10.5

1Units expressed as years.

Results of the blood glucose profile showed that all individuals were hyperglycaemic. The fasting blood glucose and HbA1c percentage among entire group was shown in Table 2.
Table 2

The concentration of fasting blood glucose and HbA1c percentage in diabetic patients

 

Normal range

Study group range

Mean

Glucose (FBG)1

Female

70 – 100

109–337

196.7 ± 61.22

Male

70 – 100

135–339

217.1 ± 57.52

HbA1c3

Female

<6.5

6.5-11.30

8.46 ± 1.494

Male

<6.5

6.5-11.40

8.84 ± 1.534

1Units expressed as mg/dl.

2Statistically significant (p < 0.001) as compared to normal range for plasma blood glucose.

3Units expressed as percentage (%).

4Statistically significant (p < 0.001) as compared to normal range for HbA1c.

Results of serum lipid profile showed that there is no statistically significant difference between diabetic females and males as TC, TG, HDL and LDL compared (p > 0.05). However, a significant difference was found as compared to normal range for related serum lipids of diabetics (p < 0.001) (Table 3).
Table 3

The results of TC, TG, HDL and LDL in serum of diabetic patients

Lipid

Female

Male

 

Normal range

Study group

Mean

Normal range

Study group

Mean

TC1

<200

137-396

227.6 ± 57.72

<200

143-292

219.1 ± 34.72

TG1

<150

89-411

221.6 ± 101.12

<150

90-432

250.0 ± 100.72

HDL1

45-65

24-50

31.5 ± 6.7

45-65

20-42

30.2 ± 7.4

LDL1

<100

69-274

136.5 ± 43.72

<100

83-161

125.7 ± 21.42

1Units expressed as mg/dl.

2Statistically significant (p < 0.001) as compared to normal range for related serum lipids.

Mean value of the TG/HDL ratio which is considered a surrogate marker of insulin resistance was 7.98 ± 3.87 among entire group. In correlation studies, TG/HDL ratio showed significant positive correlation with HbA1c (p < 0.01). Among all patients, hypercholesterolemia was found in 93 (70.5%) individuals. Similarly, increased LDL cholesterol was found in 117 (88.6%) individuals. Of the participants only 39 (29.5%) were found to have normal values for TG. Grade I and II hepatosteatosis were found in nearly one third of diabetics and Grade III hepatosteatosis in 63 (47.7%) subjects while Grade IV hepatosteatosis was found in 27 (20.5%) of the study group by hepatic ultrasound (Table 4).
Table 4

Distribution of hepatosteatosis grades among diabetics

Hepatosteatosis

No. of patients

%

Grade I

21

15.9

Grade II

21

15.9

Grade III

63

47.7

Grade IV

27

20.5

In correlation studies, FBG showed significant positive correlation with cholesterol (p < 0.05) and TG (p < 0.05). The correlation of cholesterol with TG (p < 0.001) and LDL cholesterol (p < 0.001) were positive. However, HDL cholesterol showed a negative correlation with LDL cholesterol (p < 0.01). Findings were presented in Table 5.
Table 5

Correlation studies between the blood glucose and serum lipid profile variables of diabetic patients

 

FBG

TC

TG

LDL

HDL

Hepatosteatosis

HbA1c

TG/HDL

0.5772

0.4062

0.5182

0.3161

−0.2201

0.7932

0.7722

FBG

 

0.3311

0.3621

0.213

0.061

0.7733

0.8703

TC

  

0.7193

0.8703

0.217

0.2991

0.3731

TG

   

0.3771

0.038

0.4242

0.3711

LDL

    

−0.2352

0.203

0.3311

HDL

     

−0.200

−0.043

Hepatosteatosis

      

0.9013

The values expressed as Pearson correlation co-efficients.

1Correlation is significant at the 0.05 level.

2Correlation is significant at the 0.01 level.

3Correlation is significant at the 0.001 level.

Discussion

There were more females (61.4%) than males (38.6%) with T2DM in this study. The high proportion of females in this study may be due to the nature of population admitting to this hospital in that more of them seek medical attention than men under favour of having more free time because most of them were housewives.

In patients with diabetes, many studies have clearly established that complications are mainly due to chronic hyperglycemia that exerts its injurious to health effects through several mechanisms: dyslipidemia, platelet activation, and altered endothelial metabolism [1618]. Both lipid profile and diabetes have been shown to be the important predictors for metabolic disturbances including dyslipidaemia, hypertension, cardiovascular diseases [19]. Lipids play a vital role in the pathogenesis of diabetes mellitus. Dyslipidemia as a metabolic abnormality is frequently associated with diabetes mellitus. Abnormalities in lipid metabolism have been reported in patients with diabetes mellitus accompanied by the risk of cardiovascular arteriosclerosis [20]. In the present study, significantly higher mean serum levels of total cholesterol, triglycerides and LDL cholesterol were noted in patients with diabetes, which are well known risk factors for cardiovascular diseases among patients, when compared to the normal values (Table 3).

In diabetes many factors may affect blood lipid levels, because of interrelationship between carbohydrates and lipid metabolism. Therefore, any disorder in carbohydrate metabolism leads to disorder in lipid metabolism and vice versa. Insulin resistance is a primary defect in the majority of patients with T2DM. In non-diabetic individuals insulin resistance in combination with hyperinsulinemia has a strong predictive value for future development for type 2 diabetes [21]. Several studies showed that insulin affects the liver apolipoprotein production and regulates the enzymatic activity of lipoprotein lipase and cholesterol ester transport protein, which causes dyslipidemia in diabetes mellitus. Moreover, insulin deficiency reduces the activity of hepatic lipase and several steps in the production of biologically active lipoprotein lipase [4, 22, 23]. Hypertriglyceridaemia usually accompanies decreased HDL cholesterol, which is also a prominent feature of plasma lipid abnormalities seen in individuals with diabetes [24, 25]. The cluster of lipid abnormalities associated with T2DM is defined by a high concentration of TG and small dense LDL and a low concentration of HDL cholesterol. The association between reduced HDL cholesterol levels and increased risk of heart disease is, on the other hand, well established, independently of TG levels and other risk factors [26, 27]. The possible mechanism responsible for hypertriglyceridaemia may be due to increased hepatic secretion of very low density lipoprotein (VLDL) and delayed clearance of triglyceride rich lipoproteins, which is predominantly due to increased levels of substrates for triglyceride production, free fatty acids and glucose [28]. In the present study, significant correlations were observed between serum levels of total cholesterol, triglycerides, LDL cholesterol and hepatosteatosis and blood concentrations of HbA1c (Table 5). Results of the correlation studies suggest a clear association between hyperglycemia and appearance of dyslipidemia. Our findings were in line with a previous study suggesting that the level of total cholesterol is usually normal or near normal if glycaemic control is adequate, and worsening of control raises the level [29]. Therefore, improving glycaemic control might substantially reduce the risk of cardiovascular events in diabetic patients.

Abnormal glucose reading is the commonest metabolic abnormality in people with T2DM accompanied by lower HDL levels, elevated LDL, hypercholesterolaemia, and hypertriglyceridaemia. Poor glycaemic control and hypertriglyceridaemia are significant biochemical abnormalities in patients with T2DM. Dyslipidemia management in people with diabetes mellitus, just like in any other individual, starts with a flawless evaluation that aims to identify secondary causes that might contribute to the abnormal lipid profile [30].

The triglyceride-to-HDL cholesterol (TG/HDL) ratio has been investigated recently for various potential clinical uses in adult and paediatric populations [31, 32]. Previous research has demonstrated its positive associations with adverse cardio-metabolic risk factor profiles, metabolic syndrome and prediction of incident diabetes or its complications [31, 32]. This may occur as the TG/HDL ratio demonstrates an association with insulin resistance [3133]. A number of studies have shown that the TG/HDL ratio has a good correlation with the generally accepted methods to define insulin resistance and it is considered a surrogate marker of it [34]. The significant positive correlation of TG/HDL ratio with HbA1c found in this study is in line with the studies in the literature (p < 0.01) [3134].

Although obesity and T2DM commonly co-exist [35], mean BMI in our study was in the overweight range. Subjects enrolled in the study were the patients who have diagnose of their diabetes for averagely 3 years. They were under control of a dietitian since the date of diagnose. This might be the cause that patients in our study were mostly overweight, but not obese.

Lifestyle changes, including increased physical activity and dietary modifications, are the milestones of management. There is need for increased efforts by family members, community and healthcare professionals towards preventive based approach in the management of diabetes. This can be achieved through increased emphasis on lifestyle modification strategies such as exercise, increased dietary restrictions and weight control strategies especially for those with impaired fasting glucose. Monitoring of lipid profile by blood tests done in regular intervals in primary healthcare also might play an important role to detect and take care of lipid abnormalities both in diabetics and non-diabetics. One of the strengths of this study is that it was the first study in Istanbul, Turkey that looked at association between serum lipid profile and blood glucose among patients with T2DM in primary healthcare. To the best of our knowledge, there has not been any previous study both performing blood tests and hepatic ultrasound on this group of subjects. Despite several important findings in the present study, relatively small sample size is considered as a limitation of it.

The highest priority for diabetic individuals who have poor glycaemic control should be to achieve almost near normal blood glucose levels, with the expectation that this effort will also cause an improvement in dyslipidemia [22, 36, 37]. Our study clearly shows that lipid profiles are abnormal in diabetes mellitus. Realizing that most of the diabetics have a high probability of developing cardiovascular and cerebrovascular disease, it is essential that an individual who is diabetic should take care of dyslipidemia. Our study definitely indicates the presence of hyperlipidemia which might be hazardous for diabetics.

Conclusion

The present study suggested that common lipid abnormalities during diabetes induced dyslipidemia are hypercholesterolemia, hypertriglyceridemia and elevated LDL cholesterol. Results suggest a high prevalence of dyslipidemia, which might be playing a major role in the development of cardiovascular diseases and cerebrovascular accidents among diabetic patients. The optimal care for diabetic patients should include routine monitoring of blood glucose and serum lipid profile. Efforts to achieve lifestyle changes, such as weight reduction, physical exercise and smoking cessation should be encouraged and initiated first and then followed by medication with lipid lowering drugs prescribed in evidence-based necessary conditions. The optimum treatment with proper antidiabetic drugs to obtain fair glycaemic control should go concomitantly with lipid lowering drugs as well as with taken dietary precautions. When those mentioned above are done, we might properly speak about the benefits that primary healthcare could ensure to diabetics by the advantage of monitoring patients more closely.

Methods

The cross-sectional study sample included Turkish participants diagnosed with T2DM. The study was done from January 2014 to June 2014 in the outpatient departments of Family Medicine clinic of the Bezmialem Vakif University Hospital in the largest city of Turkey, namely Istanbul, in the north-west region of the country and participating 132 subjects with T2DM (more than 6 months duration) were randomly selected and recruited in the study. The patients whose taking multi-vitamin supplementation or having hepatic, renal or metabolic bone disorders (including parathyroid related problems) were excluded from the study for the reason that those conditions might affect the carbohydrate and lipid metabolism in diabetes [38, 39]. Also those patients having history of malabsorption syndromes such as celiac disease or active malignancy or with active infection were excluded from the study. Written informed consent was taken from each subject, fulfilling the mentioned criteria at above, before study inclusion. Study subjects were asked to complete a generalized questionnaire that contains demographic information including past and present medical history, and to return after fasting for more than 8 hours for anthropometry and blood withdrawal. At the screening visit, blood samples were examined for levels of glucose and lipid profile. Subjects who had abnormal levels of these at bio-chemical laboratory tests were excluded.

Subjects were requested to visit the family medicine outpatient clinic following an overnight fasted state (≥8 hours) for anthropometry and blood withdrawal by the clinic nurse and physician on duty, respectively. Anthropometry included height (rounded to the nearest 0.5 cm), weight (rounded to the nearest 0.1 kg), and mean systolic and diastolic blood pressure (mmHg). Body mass index (BMI) was calculated as weight in kilograms divided by height in square meters. Fasting blood samples were collected and transferred immediately to a non-heparinized tube for centrifugation. Collected serum was then transferred to pre-labeled plain tubes and delivered to the bio-chemistry laboratory in Bezmialem Vakif University Hospital.

Fasting glucose, cholesterol and triglyceride were measured using an chemical auto-analyzer (Toshiba, Japan). Cholesterol esters will be hydrolyzed by cholesterol esterase. Cholesterol will be oxidized into cholest-4-en-3-on and hydrogen peroxide by bacterial cholesterol oxidase. Hydrogen peroxide in the presence of phenol and amino-4-antipyrine forms a complex of red color showing absorption maximum between 500–550 nm. It is based on the principle that triglycerides in the serum sample are hydrolyzed enzymatically by the action of lipase to glycerol and fatty acids. The glycerol formed is converted to glycerol phosphate by glycerol kinase (GK). Glycerol phosphate is then oxidized to dihydroxyacetone phosphate by glycerol phosphate oxidase (GPO). The librated hydrogen peroxide is detected by a chromogenic acceptor, chlorophenol-4-aminoantipyrine, in the presence of peroxidase (POD). The red quinone formed is proportional to the amount of triglycerides (TG) present in the sample and is measured at 546 nm. High density lipoprotein (HDL) is measured by using phosphotungstate precipitation method based on the principle that chylomicrons, very low density lipoprotein (VLDL) and low density lipoprotein (LDL) fractions in serum or plasma are separated from HDL by precipitating with phosphotungstic acid and magnesium chloride. After centrifugation the cholesterol in the HDL fraction which remains in the supernatant is assayed with enzymatic cholesterol method using cholesterol esterase, cholesterol oxidase, peroxidase and the chromogen 4-aminoantipyrine. The LDL cholesterol test is a two reagent homogenous system. The assay is comprised of two distinct phases. In phase one a unique detergent solubilizes cholesterol from non-LDL-lipoprotein particles. This cholesterol is consumed by cholesterol esterase, cholesterol oxidase, peroxidase and 4-aminoantipyrine to generate a colorless end product. In phase two a second detergent in reagent 2 releases cholesterol from the LDL lipoproteins. This cholesterol reacts with cholesterol esterase, cholesterol oxidase and a chromogen system to yield a blue color complex which can be measured bichromatically at 540/660 nm. The resulting increase in absorbance is directly proportional to the LDL concentration in the sample. The value of VLDL cholesterol was calculated as one-fifth of the concentration of triglycerides.

It should be noted that the Quality Assurance (QA) standards are maintained by TS EN ISO 15189, whereas the QA department audits the laboratory at regular intervals. Ethical approval was taken from the institutional review board (IRB) prior to the commencement of the study.

Ultrasound could be used contributively in detecting hepatosteatosis and it is a non-invasive and easily applicable method. However, liver biopsy remains the only accurate way to diagnose hepatosteatosis. There are 4 sonographic findings of diffuse fatty change in the liver characterising different grades: (1) a diffuse hyperechoic echotexture (bright liver), (2) increased liver echotexture compared with the kidneys, (3) vascular blurring, and (4) deep attenuation [40]. A hepatic ultrasound was performed for every diabetic in the study group in order to evaluate whether hepatosteatosis is present or not and, if present, to detect the grade of hepatosteatosis by a radiologist.

Data were analyzed using the Statistical Package for the Social Sciences version 16.0 (SPSS, Chicago, IL, USA). Normal continuous variables were presented as mean ± standard deviation. Test of significance was calculated by unpaired student’s t test between cases and controls. Correlation studies (Pearson’s correlation) were performed between the variables of blood glucose and serum lipid profile. Significance was set at p < 0.05.

Author’s contributions

AO designed the study, collected the data, performed the statistical analysis, drafted the manuscript. Author read and approved the final manuscript.

Declarations

Acknowledgements

The author would like to thank all the patients who have generously given their time to be involved in this study and to thank Dr. Zeynep Bakir, resident of the Family Medicine clinic, for her contribution towards the study by making substantial contribution to acquisition of data. Also, we would like to extend our heartfelt gratitude to Bezmialem Vakif University Hospital for their permission to conduct this study.

Authors’ Affiliations

(1)
Medical Faculty, Department of Family Medicine, Adnan Menderes Boulevard, Bezmialem Vakif University

References

  1. Abou-Seif MA, Youssef AA: Evaluation of some biochemical changes in diabetic patients. Clin Chim Acta. 2004, 346: 161-170. 10.1016/j.cccn.2004.03.030View ArticlePubMedGoogle Scholar
  2. Gadi R, Samaha FF: Dyslipidemia in type 2 diabetes mellitus. Curr Diab Rep. 2007, 7 (3): 228-234. 10.1007/s11892-007-0036-0View ArticlePubMedGoogle Scholar
  3. Khan SR, Ayub N, Nawab S, Shamsi TS: Triglyceride profile in dyslipidaemia of type 2 diabetes mellitus. J Coll Phys Surg Pak. 2008, 18 (5): 270-273.Google Scholar
  4. Elinasri HA, Ahmed AM: Patterns of lipid changes among type 2 diabetes patients in Sudan. East Mediterr Health J. 2008, 14 (2): 314-324.Google Scholar
  5. Unalacak M, Kara IH, Baltaci D, Ozgur E, Bucaktepe PGE: Effects of Ramadan fasting on biochemical and hematological parameters and cytokines in healthy and obese individuals. Met Synd Rel Disord. 2011, 9 (2): 157-161. 10.1089/met.2010.0084.View ArticleGoogle Scholar
  6. Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988, 37: 1595-1607. 10.2337/diab.37.12.1595View ArticlePubMedGoogle Scholar
  7. Kaplan NM: The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridaemia and hypertension. Arch Intern Med. 1989, 149: 1514-1520. 10.1001/archinte.1989.00390070054005View ArticlePubMedGoogle Scholar
  8. Zimmet P, Alberti G, Shaw J: A new IDF worldwide definition of the metabolic syndrome: the rationale and the results. Diabetes Voice. 2005, 50 (3): 31-33.Google Scholar
  9. Taskinen MR: Diabetic dyslipidemia. Atheroscler Suppl. 2002, 3 (1): 47-51. 10.1016/S1567-5688(01)00006-XView ArticlePubMedGoogle Scholar
  10. Folli F, Corradi D, Fanti P, Davalli A, Paez A, Giaccari A, Perego C, Muscogiuri G: The role of oxidative stress in the pathogenesis of type 2 diabetes mellitus micro- and macrovascular complications: avenues for a mechanistic-based therapeutic approach. Curr Diabetes Rev. 2011, 7 (5): 313-324. 10.2174/157339911797415585View ArticlePubMedGoogle Scholar
  11. Maritim AC, Sanders RA, Watkins JB: Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol. 2003, 17 (1): 24-38. 10.1002/jbt.10058View ArticlePubMedGoogle Scholar
  12. Mahato RV, Gyawali P, Raut PP, Regmi P, Khelanand PS, Dipendra RP, Gyawali P: Association between glycaemic control and serum lipid profile in type 2 diabetic patients: glycated haemoglobin as a dual biomarker. Biomed Res. 2011, 22 (3): 375-380.Google Scholar
  13. Wexler DJ, Grant RW, Meigs JB, Nathan DM, Cagliero E: Sex disparities in treatment of cardiac risk factors in patients with type 2 diabetes. Diabetes Care. 2005, 28 (3): 514-520. 10.2337/diacare.28.3.514View ArticlePubMedGoogle Scholar
  14. Regmi P, Gyawali P, Shrestha R, Sigdel M, Mehta KD, Majhi S: Pattern of dyslipidemia in type-2 diabetic subjects in Eastern Nepal. J Nepal Assoc Med Lab Sci. 2009, 10 (1): 11-13.Google Scholar
  15. Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, Coresh J, Brancati FL: Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med. 2010, 362: 800-811. 10.1056/NEJMoa0908359PubMed CentralView ArticlePubMedGoogle Scholar
  16. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature. 2001, 414 (6865): 813-820. 10.1038/414813aView ArticlePubMedGoogle Scholar
  17. Jokl R, Colwell JA: Arterial thrombosis and atherosclerosis in diabetes. Diabetes Metab Rev. 1997, 5: 1-15.Google Scholar
  18. Taskinen MR: Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia. 2003, 46 (6): 733-749. 10.1007/s00125-003-1111-yView ArticlePubMedGoogle Scholar
  19. Goldberg IJ: Diabetic dyslipidemia: causes and consequences. J Clin Endocr Metab. 2001, 8 (3): 965-971.View ArticleGoogle Scholar
  20. Krauss RM: Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care. 2004, 27 (6): 1496-1504. 10.2337/diacare.27.6.1496View ArticlePubMedGoogle Scholar
  21. Haffner SM, Mykkanen L, Festa A: Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects. Circulation. 2000, 101: 975-980. 10.1161/01.CIR.101.9.975View ArticlePubMedGoogle Scholar
  22. Mooradian AD: Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocr Metab. 2009, 5: 150-159. 10.1038/ncpendmet1066.View ArticleGoogle Scholar
  23. Smith S, Lall AM: A Study on lipid profile levels of diabetics and non-diabetics among Naini region of Allahabad, India. Turk J Biochem. 2008, 33 (4): 138-141.Google Scholar
  24. Howard BV: Lipoprotein metabolism in diabetes mellitus. J Lipid Res. 1987, 28 (6): 613-628.PubMedGoogle Scholar
  25. Taskinen MR, Kahri J, Koivisto V, Shepherd J, Packard J: Metabolism of HDL apolipoprotein A-I and A-II in type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1992, 35 (4): 347-356. 10.1007/BF00401202View ArticlePubMedGoogle Scholar
  26. Bitzur R, Cohen H, Kamari Y, Shaish A, Harats D: Triglycerides and HDL Cholesterol: Stars or second leads in diabetes?. Diabetes Care. 2009, 32 (2): 373-377.View ArticleGoogle Scholar
  27. Goldbourt U, Yaari S, Medalie JH: Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality: a 21-year follow-up of 8000 mMen. Arterioscler Thromb Vasc Biol. 1997, 17: 107-113. 10.1161/01.ATV.17.1.107View ArticlePubMedGoogle Scholar
  28. Goldberg IJ: Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J Lipid Res. 1996, 37 (4): 693-707.PubMedGoogle Scholar
  29. Andersen GE, Christiansen JS, Mortensen HB, Christiansen KM, Pedersen-Bjergaard L, Kastrup KW, Vestermark S: Serum lipids and lipoproteins in 157 insulin dependent diabetic children and adolescents in relation to metabolic regulation, obesity and genetic hyperlipoprotenimia. Acta Paediatr Scand. 1983, 72: 361-365. 10.1111/j.1651-2227.1983.tb09729.xView ArticlePubMedGoogle Scholar
  30. Hachem SB, Mooradian AD: Familial dyslipidaemias: an overview of genetics, pathophysiology and management. Drugs. 2006, 66: 1949-1969. 10.2165/00003495-200666150-00005View ArticlePubMedGoogle Scholar
  31. He S, Wang S, Chen X, Jiang L, Peng Y, Li L, Wan L, Cui K: Higher ratio of triglyceride to high-density lipoprotein cholesterol may predispose to diabetes mellitus: 15-year prospective study in a general population. Metabolism. 2012, 61 (1): 30-36. 10.1016/j.metabol.2011.05.007View ArticlePubMedGoogle Scholar
  32. Zoppini G, Negri C, Stoico V, Casati S, Pichiri I, Bonora E: Triglyceride-highdensity lipoprotein cholesterol is associated with microvascular complications in type 2 diabetes mellitus. Metabolism. 2012, 61 (1): 22-29. 10.1016/j.metabol.2011.05.004View ArticlePubMedGoogle Scholar
  33. Giannini C, Santoro N, Caprio S, Kim G, Lartaud D, Shaw M, Pierpont B, Weiss R: The triglyceride-to-HDL cholesterol ratio: association with insulin resistance in obese youths of different ethnic backgrounds. Diabetes Care. 2011, 34 (8): 1869-1874. 10.2337/dc10-2234PubMed CentralView ArticlePubMedGoogle Scholar
  34. Kim-Dorner SJ, Deuster PA, Zeno SA, Remaley AT, Poth M: Should triglycerides and the triglycerides to high-density lipoprotein cholesterol ratio be used as surrogates for insulin resistance?. Metabolism. 2010, 59 (2): 299-304. 10.1016/j.metabol.2009.07.027View ArticlePubMedGoogle Scholar
  35. Sattar N, Gill JMR: Type 2 diabetes as a disease of ectopic fat?. BMC Med. 2014, 12: 123-PubMed CentralView ArticlePubMedGoogle Scholar
  36. Siraj ES, Seyoum B, Saenz C, Abdulkadir J: Lipid and lipoprotein profile in Ethopian patients with diabetes mellitus. Metabolism. 2006, 55 (6): 706-710. 10.1016/j.metabol.2005.08.002View ArticlePubMedGoogle Scholar
  37. Al-Habori M, Al-Mamari M, Al-Meeri A: Type II diabetes mellitus and impaired glucose tolerance in Yemen: frequency, associated metabolic changes and risk factors. Diabetes Res Clin Pract. 2004, 65: 275-281. 10.1016/j.diabres.2004.02.001View ArticlePubMedGoogle Scholar
  38. Heshmat R, Tabatabaei-Malazy O, Abbaszadeh-Ahranjani S, Shahbazi S, Khooshehchin G, Bandarian F, Larijani B: Effect of vitamin D on insulin resistance and anthropometric parameters in Type 2 diabetes; a randomized double-blind clinical trial. DARU J Pharm Sci. 2012, 20: 10-10.1186/2008-2231-20-10.View ArticleGoogle Scholar
  39. Wu P: Thyroid disease and diabetes. Clin Diab. 2000, 18 (1): 38-Google Scholar
  40. American Gastroenterological Association: AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 2002, 123: 1705-1725. 10.1053/gast.2002.36572View ArticleGoogle Scholar

Copyright

© Ozder; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.